<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855647</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11022007-792</org_study_id>
    <secondary_id>79432</secondary_id>
    <secondary_id>PROS0020</secondary_id>
    <nct_id>NCT00855647</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)</brief_title>
  <official_title>Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated
      radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and
      effective in the treatment of low-risk localized prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response that achieves a stable nadir over time.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">99999</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypo-fractionated Radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial
        PSA level &lt;10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores
        involved.

          -  Patients who have had any form of prior curative treatment (surgery, radiotherapy,
             cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3
             months duration will be allowed.

          -  Adult men will be considered.

          -  No life expectancy restrictions will apply.

          -  Performance Status will not be considered.

          -  No requirements for organ or marrow function will be made

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:- No prior prostate treatment will be allowed.

          -  The use of other concurrent Investigational Agents will not be allowed.

          -  No exclusion requirements due to co-morbid disease or incurrent illness.

          -  No requirements regarding history of allergic reactions.

          -  Pregnancy or nursing patients is not applicable (ie. patients are male).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher R. King</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2009</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christopher R. King</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

